The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | IMGN632: a novel CD123 ADC for R/R AML and BPDCN
Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the phase I study (NCT03386513) investigating the novel CD123-targeting antibody-drug conjugate IMGN632, which holds promise for treating R/R acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), and other CD123-positive malignancies. Dr Daver highlights how this agent will be moving forwards, and discusses the combinations that are planned. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
